G

GSK

Develops medicines, vaccines, and consumer health

Regulatory Manager - Strategy, CMC RA Vaccines Development Projects

Full-TimeUpdated Deadline 11/4/26
$103.5k - $189.8k/yr+ Annual bonus + Share-based long-term incentive
Mid
Bachelor's, PhD
Boston, MA, USA+5 moreMore locations: Wavre, Belgium | Upper Providence Township, PA, USA | Siena, Italy | Warsaw, Poland | United States
HybridHybrid work (remote and on-site) is available at listed locations.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A Bachelor of Science in life sciences or a related scientific discipline, or a PhD.
  • Experience in Chemistry, Manufacturing and Controls regulatory affairs or product development, with direct involvement in preparing regulatory submissions across all development stages through early lifecycle submissions.
  • Sound knowledge of drug development, manufacturing processes, and supply chain, with a specialized area of expertise potentially applicable.
  • Knowledge of worldwide Chemistry, Manufacturing and Controls regulatory requirements and a successful track record of delivering compliant dossiers, particularly for new medicines in development.
  • Ability to plan, prioritize, and coordinate multiple tasks effectively and adjust to changing priorities to meet tight deadlines.
  • Continued professional growth in global regulatory affairs, including communicating emerging trends and policies and understanding implications across projects.
  • Experience influencing and negotiating with company personnel and regulatory agencies in varied settings.
  • Strong interpersonal, presentation, and communication skills, with established internal networks.
  • Ability to proactively recommend process improvements.
  • Proven ability to develop and implement regulatory strategies and evaluate their potential impact on overall project and product strategy.
  • Ability to handle global Chemistry, Manufacturing and Controls issues through continuous change and improvement.
  • Developing experience in major filing activities, significant manufacturing changes, and key development interactions at end of Phase 2/pre-Phase 3 or other early-development regulatory interactions.
Responsibilities
  • Be responsible for global Chemistry, Manufacturing and Controls regulatory activities for assigned projects and respond readily to changing events and priorities.
  • Develop Chemistry, Manufacturing and Controls strategy, with managerial support, for submission documents from early-phase clinical submissions (IND/IMPD) through marketing applications (NDA/BLA/MAA) and early lifecycle management activities, in accordance with applicable regulatory and scientific standards.
  • Understand and interpret regulations, guidelines, procedures, and policies relating to development, registration, and manufacture of medicinal products, and sometimes advise teams on them to expedite submission, review, and approval of global Chemistry, Manufacturing and Controls applications.
  • Ensure appropriate Chemistry, Manufacturing and Controls regulatory aspects for clinical trials and product release are in place to avoid clinical holds and ensure continuity of market supply.
  • Ensure information submitted in clinical and marketing applications meets regional requirements, allowing maximum supply, production, and quality flexibility with minimal unanticipated questions.
  • Work in cross-functional matrix project teams with regulatory, development, quality, and manufacturing colleagues to define an appropriate regulatory Chemistry, Manufacturing and Controls filing strategy.
  • Maintain high quality standards and seek to raise performance through continuous improvement and innovative responses to the evolving regulatory environment.
  • Ensure regulatory compliance and share best practices and learnings within the Chemistry, Manufacturing and Controls Regulatory teams and other impacted functions.
  • Engage in internal Chemistry, Manufacturing and Controls subject matter expert activities to improve compliance, harmonization, and efficiency.
  • Sometimes deliver Chemistry, Manufacturing and Controls regulatory strategy to support major inspections, such as pre-approval inspections, with managerial support.
Desired Qualifications
  • May be identified as a Chemistry, Manufacturing and Controls Regulatory expert in a specific subject area.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 28th, 2026
GSK Q3 sales rise 5% to $11.3B as specialty medicines drive growth, 2026 guidance reaffirmed

GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, driven by specialty medicines. Core operating profit rose 5%, while core earnings per share rose 1%. The company reaffirmed its 2026 guidance, expecting sales and core operating profit in the upper half of their ranges. Higher interest costs after the $10.6 billion Nuvalent acquisition will hold core earnings per share growth in the lower half of its range. Specialty medicines grew 15%, led by Cabenuva, up 35%. Vaccines sales fell 2% on Shingrix destocking in China. Research and development spending rose 22%. GSK has started 18 phase III studies this year and expects four more. It declared a third-quarter dividend of 17 pence per share.

Yahoo Finance
Oct 28th, 2026
GSK shares slide as pipeline doubts and weak vaccine sales offset $11.3B sales beat

GSK shares fell about 4% on October 28 despite a third-quarter sales and profit beat, as investors focused on pipeline doubts and weak vaccine sales, including shingles shot Shingrix. The stock fell as much as 7.3% earlier in the day. Core profit was 54.6 pence per share on turnover of £8.89 billion, against expectations of 50.4 pence and £8.84 billion. Specialty medicines for HIV, respiratory conditions and cancer rose 15%, but sales of new asthma drug Exdensur and vaccines missed forecasts. Chief executive officer Luke Miels is running a £1.9 billion ($2.5 billion) cost-savings plan to fund drug development ahead of patent losses. Market forecasts for 2031 sales of £36.64 billion trail GSK's target of more than £40 billion. GSK kept its annual outlook and took a £328 million restructuring charge in the quarter.

Yahoo Finance
Oct 28th, 2026
FTSE 100 slips 0.3% ahead of budget as GSK falls 4.3% and Unilever drops 3.4% despite earnings beats

British stocks fell on Wednesday as investors awaited the budget and weighed results from GSK and Unilever. The FTSE 100 was down 0.30% at 08:18 GMT, extending Tuesday's fall. GSK was the top loser, down 4.3%, despite beating third-quarter expectations. Core earnings per share were 54.6 pence against a consensus of 50.4 pence, and revenue was £8.89 billion. Unilever fell 3.38% even after it raised its volume growth forecast to at least 3%. Finance Minister John Healey said he would scrap gas standing charges, which cost the typical household £108 a year. Standard Chartered raised its full-year targets after third-quarter pretax profit jumped 27% to $2.25 billion. Brent futures rose 1.4% to $110.91 a barrel.

Yahoo Finance
Oct 28th, 2026
GSK holds guidance as specialty drugs lift sales 5% to $11.3B, but $417M charge cuts profit 16%

GSK kept its 2026 guidance after specialty medicines drove another quarter of growth, though a £328 million restructuring charge cut its profit. Sales rose 5% at constant exchange rates to £8.9 billion. Core operating profit rose 5% to £3.1 billion, while total operating profit fell 16% to £2.1 billion. The charge relates to Accelerate Growth, a cost-cutting programme that targets £1.9 billion of annual savings by 2029 at a total cost of £2.4 billion. GSK plans to put the savings mainly into research and development. Specialty medicines grew 15% to £3.9 billion, while vaccines fell 2% to £2.6 billion. Net debt rose to £20.7 billion from £14.5 billion at the end of 2025, after the $10.8 billion Nuvalent takeover. Chief executive Luke Miels said GSK had "delivered another strong quarter.

Yahoo Finance
Oct 27th, 2026
GSK's oncology push: Jemperli FDA approval and strong ADC data at ESMO for $97.4B group

GSK presented late-stage oncology data at the ESMO Congress in October 2026 on three drugs: Jemperli, Mo-Rez and Ris-Rez. The £76.7 billion pharmaceuticals group is leaning on oncology as a key part of its mix. The US Food and Drug Administration (FDA) granted Jemperli accelerated approval for MSI-H/dMMR locally advanced rectal cancer. In the AZUR-1 trial, 71% of patients received dostarlimab alone, without additional treatment or progression in the assessment window. Mo-Rez showed a 62% confirmed response rate in platinum-resistant ovarian and endometrial cancers, with a median duration of 12.2 months. Ris-Rez delivered a 61% objective response rate in extensive stage small cell lung cancer. Investors should watch the phase III trials and AZUR-1 follow-up data.